Optic nerve glioma is a primary tumor of the optic nerve, and the vast majority have pilocytic astrocytoma (WHO Grade I) histology. It is the most common optic nerve tumor in children, and 15-40% of cases are associated with neurofibromatosis type 1 (NF1). NF1-associated cases generally have a better prognosis and may show spontaneous regression. The tumor presents as fusiform (spindle-shaped) optic nerve thickening and may extend to the optic chiasm and optic tract. Bilateral optic nerve glioma is pathognomonic for NF1. Vision loss, proptosis, and optic disc edema/atrophy are the most common clinical findings.
Age Range
2-15
Peak Age
5
Gender
Equal
Prevalence
Rare
Optic nerve glioma originates from neuroglial cells (astrocytes) of the optic nerve, and in pilocytic astrocytoma histology shows bipolar cell morphology, Rosenthal fibers, and eosinophilic granular bodies. Tumor development in NF1 is related to uncontrolled activation of the RAS-MAPK signaling pathway due to loss of neurofibromin (NF1 gene product), leading to glial cell proliferation. The tumor typically grows in the interstitial spaces of the optic nerve, pushing nerve fibers apart and causing fusiform enlargement. Perineural arachnoid proliferation (meningohyperplasia) appears as kinking and tortuous enlargement on MRI and contributes to the tumor boundaries covering a wide area along the nerve. Cystic degeneration and mucinous material accumulation cause T2 hyperintensity and enhancement heterogeneity. Extension to the optic chiasm may lead to hydrocephalus and hypothalamic dysfunction.
Fusiform (spindle-shaped) enlargement of the optic nerve with kinking along the nerve trajectory is the most characteristic finding of optic nerve glioma. Kinking results from the combined effect of perineural arachnoid proliferation and tumor expansion along the nerve. Bilateral fusiform thickening is pathognomonic for NF1.
Fusiform (spindle-shaped) thickening of the optic nerve is seen on T1-weighted images. The tumor is generally isointense or slightly hypointense relative to the optic nerve parenchyma. The normal smooth contours of the optic nerve may be preserved or become irregular. A gradual enlargement pattern is seen along the nerve, and boundaries are generally well-defined. Areas of cystic degeneration appear hypointense on T1. Thickening beginning in the intraorbital segment may extend to the intracanalicular segment and optic chiasm. Bilateral involvement strongly suggests NF1 association. Additional enlargement around the nerve may be seen due to perineural arachnoid hyperplasia.
Report Sentence
Fusiform thickening of the optic nerve is noted, showing isointense-to-slightly hypointense signal characteristics relative to nerve parenchyma on T1-weighted images, consistent with optic nerve glioma.
Optic nerve glioma shows hyperintense signal on T2-weighted images, and tumor boundaries are clearly evaluated. Areas of cystic degeneration show prominent T2 hyperintensity and can be distinguished from solid components. Perineural arachnoid proliferation (meningohyperplasia) may create an additional T2 hyperintense ring around the tumor. The optic nerve sheath may be enlarged, and increased subarachnoid space may be seen. Extension to the optic chiasm is best evaluated on T2 sequences; thickening and signal increase in the chiasm are findings of extension. Accompanying T2 hyperintense lesions in brain parenchyma (unidentified bright objects — UBOs) in NF1 patients support the NF1 diagnosis.
Report Sentence
Hyperintense signal with fusiform thickening of the optic nerve is noted on T2-weighted images, with areas of cystic degeneration also present, consistent with optic nerve glioma.
Variable enhancement pattern of optic nerve glioma is seen on contrast-enhanced fat-suppressed T1-weighted images. Solid components may show homogeneous or heterogeneous enhancement. Enhancement is seen in the wall of cystic components while cyst contents do not enhance. Enhancement degree is related to tumor grade, vascularity, and degree of blood-brain barrier disruption. Enhancement is generally less prominent in NF1-associated cases. In case of extension to the optic chiasm, chiasmal enhancement should be carefully evaluated. Fat suppression technique eliminates orbital fat signal, making enhancement much more conspicuous.
Report Sentence
The optic nerve mass shows heterogeneous enhancement on contrast-enhanced fat-suppressed T1-weighted images, with solid and cystic components being distinguished.
Fusiform thickening of the optic nerve is seen on contrast-enhanced CT, and the tumor shows homogeneous or heterogeneous enhancement. Optic canal widening (bone window reformat) indicates intracanalicular extension of the tumor. Calcification is rare and when present, optic nerve sheath meningioma should be considered in the differential diagnosis. Bone remodeling (optic canal widening, anterior clinoid process erosion) indicates chronic compression by the slowly growing tumor. CSF space surrounding the tumor (subarachnoid space widening) may be seen. CT is less sensitive compared to MRI but is useful for urgent assessment and bone detail.
Report Sentence
Fusiform thickening and enhancement of the optic nerve is noted on contrast-enhanced CT, with bone remodeling consistent with optic canal widening on bone window images.
Increased optic nerve diameter (normal <5 mm) is seen on B-mode orbital ultrasonography. The tumor is generally of low-to-moderate echogenicity with homogeneous or slightly heterogeneous structure. Fusiform enlargement pattern of the optic nerve can be evaluated on axial sections. Cystic components appear as anechoic areas. Orbital ultrasonography is valuable as an initial assessment tool especially in children due to its noninvasive, radiation-free, and easily applicable nature. However, the posterior part of the optic canal and extension to the optic chiasm cannot be evaluated by ultrasonography; therefore, it must be complemented with MRI.
Report Sentence
Increased optic nerve diameter and fusiform enlargement is noted on orbital ultrasonography, and MRI correlation is recommended for intracranial evaluation.
In NF1-associated optic nerve glioma, multiple T2/FLAIR hyperintense lesions in brain parenchyma (UBOs — unidentified bright objects or focal areas of signal intensity — FASI) may be seen on FLAIR sequences. These lesions are most commonly located in basal ganglia (especially globus pallidus), cerebellum (dentate nucleus), brainstem, and thalamus. They reflect myelin vacuolization and show no mass effect or enhancement. They generally show spontaneous resolution around age 20. The presence of UBOs together with optic nerve glioma strongly supports the NF1 diagnosis. Optic chiasm and tract involvement are also optimally evaluated on FLAIR sequences.
Report Sentence
In addition to the optic nerve glioma, multiple T2/FLAIR hyperintense lesions (UBOs) in the basal ganglia and cerebellum are noted on FLAIR sequences, consistent with NF1-associated findings.
Criteria
Optic nerve glioma in a patient with neurofibromatosis type 1. Accounts for 15-40% of cases. Bilateral involvement is pathognomonic for NF1. NF1 diagnostic criteria: ≥6 café-au-lait spots, neurofibromas, axillary/inguinal freckling, optic glioma, Lisch nodules, bone dysplasia, first-degree relative with NF1.
Distinct Features
Generally better prognosis and indolent course. May show spontaneous regression and observation may be preferred. Bilateral involvement is seen only in NF1. UBOs in brain parenchyma accompany. Chemotherapy (carboplatin + vincristine) is first-line treatment in case of progression. Radiation therapy should be avoided in NF1 due to risk of secondary malignancy.
Criteria
Optic nerve glioma developing without NF1. Accounts for 60-85% of cases. Usually shows unilateral involvement. More aggressive course and risk of progression may be higher compared to NF1-associated cases.
Distinct Features
No NF1 stigmata present. UBOs are not seen. Higher risk of progression requiring closer follow-up. Surgical resection, chemotherapy, or radiation therapy options are considered in treatment planning. Tumor location and extent determine treatment decision.
Criteria
Optic pathway glioma involving the optic chiasm and/or hypothalamus. Requires more challenging management due to larger tumor volume and more complex surgical access. Risk of hydrocephalus, endocrine dysfunction, and bilateral vision loss is high.
Distinct Features
MRI shows chiasm thickening and enhancement with hypothalamic extension. Third ventricle compression may lead to hydrocephalus. Diencephalic syndrome (cachexia, nystagmus, excessive sleepiness) may be seen especially in infant patients. Endocrine evaluation (growth hormone, thyroid function, cortisol) is mandatory.
Criteria
Rare, high-grade (anaplastic astrocytoma or glioblastoma) optic nerve glioma occurring in adults. Shows very different aggressive biological behavior compared to childhood pilocytic astrocytoma. Characterized by rapid progression and poor prognosis.
Distinct Features
Rapid progressive vision loss and pain. Heterogeneous enhancement, necrosis areas, and aggressive growth pattern on MRI. Rapid spread to contralateral optic nerve and chiasm. Median survival is less than 1 year. Radiation therapy and chemotherapy are palliative.
Distinguishing Feature
Optic nerve sheath meningioma is seen in middle-aged women (glioma in children), shows tram-track sign (axial) and doughnut sign (coronal). Calcification is common in meningiomas, rare in gliomas. In meningiomas, the optic nerve is seen SEPARATELY, while in gliomas the nerve ITSELF is enlarged. Enhancement pattern differs: peripheral sheath enhancement in meningiomas, central nerve enhancement in gliomas.
Distinguishing Feature
Optic neuritis presents with acute vision loss and shows enhancement and T2 signal increase of the optic nerve on MRI but without significant mass effect or fusiform enlargement. Optic nerve diameter may be normal or slightly increased. Clinical course differs: neuritis usually resolves within weeks while glioma shows chronic-progressive course. Multiple sclerosis association and demographic profile (young women) are also distinguishing.
Distinguishing Feature
Orbital lymphoma typically appears as a homogeneous mass localized to the lacrimal gland or extraconal space and is not specific to the optic nerve. Moulding pattern and low ADC values are typical. Lymphoma encasing the optic nerve rarely causes fusiform enlargement; rather shows circumferential encasement. Cystic degeneration is rare in lymphoma, common in glioma. Age distribution differs: lymphoma in older adults, glioma in children.
Distinguishing Feature
Retinoblastoma is an intraocular mass showing calcification (95%+). It may secondarily invade the optic nerve but the primary lesion is intraocular. Calcification is rare in glioma and the primary lesion is in the optic nerve. Retinoblastoma is usually seen in children under 5 years, while optic nerve glioma presents in a slightly wider age range (2-10 years).
Urgency
routineManagement
surveillanceBiopsy
Not NeededFollow-up
NF1 ilişkili: 6-12 ayda bir MR, görme muayenesi ve oftalmolojik değerlendirme. Sporadik: 3-6 ayda bir MR takip. Kiazmaya uzanım varsa endokrin ve nörolojik takip eklenmeli.Management of optic nerve glioma depends on NF1 association, tumor extent, and visual status. In NF1-associated cases, observation is the primary approach due to indolent course, and treatment is initiated only in case of progression (vision loss, tumor growth). Progression risk is higher in sporadic cases. First-line treatment is carboplatin + vincristine chemotherapy. Radiation therapy should be avoided in NF1 patients due to risk of secondary malignancy (especially malignant peripheral nerve sheath tumor). Surgery may be considered for eyes with established blindness in case of severe proptosis or cosmetic concern. Vision preservation is the most critical factor in treatment decisions.
NF1-associated gliomas are typically indolent and observed. Chemotherapy (carboplatin/vincristine) is administered for vision loss or chiasmatic extension. Surgical risk is vision loss. Routine ophthalmologic screening is needed in children diagnosed with NF1.